<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661215</url>
  </required_header>
  <id_info>
    <org_study_id>12 DK PSAGS</org_study_id>
    <secondary_id>U24DK074008</secondary_id>
    <secondary_id>U01DK073974</secondary_id>
    <secondary_id>U01DK074007</secondary_id>
    <secondary_id>U01DK074035</secondary_id>
    <secondary_id>U01DK073975</secondary_id>
    <secondary_id>U01DK112193</secondary_id>
    <secondary_id>U01DK073983</secondary_id>
    <nct_id>NCT04661215</nct_id>
  </id_info>
  <brief_title>Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms</brief_title>
  <acronym>PSAGS</acronym>
  <official_title>Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine if there are pyloric sphincter&#xD;
      abnormalities in patients with gastroparesis symptoms and determine how prevalent these&#xD;
      abnormalities are using three tests to assess the pyloric sphincter - endoluminal functional&#xD;
      luminal imaging probe (Endoflip™), electrogastrography (EGG) with water load satiety testing&#xD;
      (WLST), and wireless motility capsule (WMC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have been several published studies using Endoflip™ to assess the pyloric sphincter in&#xD;
      small number of participants. In the first study, Gourcerol et al showed that pyloric&#xD;
      compliance is decreased in gastroparesis patients compared to 21 healthy controls and&#xD;
      associated with the T1/2 of gastric emptying and symptoms of gastroparesis (Gourcerol 2015).&#xD;
      From this study, pyloric distensibility &lt;10 appeared to be abnormal. In the second study,&#xD;
      Malik et al found that the pyloric sphincter contour was seen best at distention with 40 cc.&#xD;
      Symptoms of early satiety and postprandial fullness were inversely correlated with pyloric&#xD;
      diameter and cross-sectional area of the pyloric sphincter (Malik 2015).&#xD;
&#xD;
      Pyloric distensibility &lt;9.2 was associated with improvement in symptoms with endoscopic&#xD;
      pyloromyotomy. A recent study showed similar patterns for improvement in symptoms with&#xD;
      botulinum toxin injection in the pylorus.&#xD;
&#xD;
      The pyloric sphincter is at the distal end of the stomach, whereas the lower esophageal&#xD;
      sphincter (LES) is at the proximal portion of the stomach. How abnormalities of the pyloric&#xD;
      sphincter relate to abnormalities of the LES is not known, but will be addressed in this&#xD;
      study. Our prior studies have shown that diffuse transit abnormalities may occur in patients&#xD;
      with gastroparesis. In addition, patients with gastroparesis can have symptoms of&#xD;
      gastroesophageal reflux disease. This study will ascertain if there are LES abnormalities in&#xD;
      patients with gastroparesis as determined by Endoflip™, such as LES distensibility and how&#xD;
      LES distensibility relates to pyloric distensibility. This study protocol will assess lower&#xD;
      esophageal and pyloric sphincter diameter, CSA, pressure, distensibility, and compliance in&#xD;
      patients with symptoms of gastroparesis and delayed gastric emptying, patients with symptoms&#xD;
      of gastroparesis but with normal gastric emptying, and normal control participants. The&#xD;
      protocol will also use two additional tests that may assess the pylorus: electrogastrography&#xD;
      (EGG) with water load satiety testing (WLST), and wireless motility capsule (WMC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distensibility of the pylorus</measure>
    <time_frame>Baseline</time_frame>
    <description>Distensibility of the pylorus will be calculated as the median of three measurements (not three different inflations) of distensibility (mm2/mmHg) of the pylorus pressure using the Endoflip balloon catheter at 50 mL volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opening diameter (mm) of the pylorus when 40 mL volume is introduced into the EF325N Endoflip™ measurement catheter.</measure>
    <time_frame>Baseline</time_frame>
    <description>diameter (mm) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opening diameter (mm) of the pylorus when 50 mL volume is introduced into the EF325N Endoflip™ measurement catheter.</measure>
    <time_frame>Baseline</time_frame>
    <description>diameter (mm) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross Sectional Area(mm2) of the pylorus with 40 mL balloon volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Cross Sectional Area (mm2) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross Sectional Area(mm2) of the pylorus with 50 mL balloon volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Cross Sectional Area (mm2) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance (mm3/mmHg) of the pylorus with 40 mL balloon volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Compliance (mm3/mmHg) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance (mm3/mmHg) of the pylorus with 50 mL balloon volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Compliance (mm3/mmHg) of the pylorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure (mmHg) of the pyloric sphincter</measure>
    <time_frame>Baseline</time_frame>
    <description>Pressure (mmHg) of the pyloric sphincter</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Idiopathic Gastric Motility Disorder</condition>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Symptoms of gastroparesis</arm_group_label>
    <description>Participants with symptoms of gastroparesis with minimum GCSI score of 2.0 (18/45 x 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control participants</arm_group_label>
    <description>Non-diabetic participant undergoing endoscopy for evaluation but without gastroparesis symptoms or gastroesophageal reflux symptoms. Score 1.0 or less (≤ 1 ) on the GCSI of PAGI-SYM questionnaire</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will be 150 adult men and women aged 18-75 years, located in the&#xD;
        United States, 100 will have symptoms of gastroparesis and 50 will be normal controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS:&#xD;
&#xD;
          -  1. Provision of signed and dated informed consent form 2. Stated willingness to comply&#xD;
             with all study procedures and availability for the duration of the study 3. Male or&#xD;
             female, aged 18 - 85 4. Symptoms of gastroparesis, either diabetic or idiopathic&#xD;
             etiology 5. Individual will have had a prior 4-hour gastric emptying scintigraphy test&#xD;
             performed for clinical evaluation within the last 6 months. This gastric emptying test&#xD;
             would be done for clinical evaluation and is not part of the research study. From&#xD;
             these participants with gastroparesis symptoms, we will include those with delayed&#xD;
             gastric emptying as well as those with normal gastric emptying.&#xD;
&#xD;
             6. Symptoms of gastroparesis with minimum GCSI score of 2.0 (18/45 x 5) 7. Willingness&#xD;
             to:&#xD;
&#xD;
               1. Stop taking proton pump inhibitors, cannabinoids, and CBD for 7 days prior to WMC&#xD;
                  ingestion&#xD;
&#xD;
               2. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin,&#xD;
                  domperidone, prucalopride), narcotics, anticholinergics, constipation medications&#xD;
                  (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte&#xD;
                  preparations (e.g. MiraLax), and prescription laxatives (e.g. lubiprostone) for 3&#xD;
                  days prior to the WMC visit;&#xD;
&#xD;
               3. Abstain from prokinetics, cannabinoids and CBD, and 'over the counter' laxatives,&#xD;
                  isotonic PEG electrolyte preparations (e.g. MiraLax), and prescription laxatives&#xD;
                  (e.g. lubiprostone, Linzess, Trulance) after ingesting the SmartPill™ until they&#xD;
                  return for the follow-up visit in 2-5 days. Proton pump inhibitors may be taken&#xD;
                  24 hours after SmartPill™ ingestion.&#xD;
&#xD;
               4. Abstain from food and water after midnight (at least for 8 hours) before the&#xD;
                  start of each visit until after the visit.&#xD;
&#xD;
               5. Abstain from cannabinoids and CBD (cannabidiol) 7 days before the EGG with water&#xD;
                  load satiety test INCLUSION CRITERIA FOR CONTROL PARTICIPANTS&#xD;
&#xD;
                    1. Provision of signed and dated informed consent form&#xD;
&#xD;
                    2. Stated willingness to comply with study procedures&#xD;
&#xD;
                    3. Male or female, aged 18 -85&#xD;
&#xD;
                    4. Non-diabetic participant without gastroparesis symptoms or gastroesophageal&#xD;
                       reflux symptoms undergoing an endoscopy for clinical evaluation.&#xD;
&#xD;
                    5. Score 1.0 or less (≤ 1 ) on the GCSI of PAGI-SYM questionnaire&#xD;
&#xD;
                       EXCLUSION CRITERIA:&#xD;
&#xD;
          -  1. Prior gut lumen surgery on the esophagus or the stomach, including Nissen&#xD;
             fundoplication.&#xD;
&#xD;
             2. Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical&#xD;
             pyloromyotomy) 3. Known history of achalasia or esophageal stricture 4. Known history&#xD;
             of physiological or mechanical GI obstruction 5. Abnormalities seen on a prior upper&#xD;
             endoscopy placing patient at increased risk:&#xD;
&#xD;
          -  Ulcer of the esophagus, stomach, or duodenum&#xD;
&#xD;
          -  Esophageal varices 6. Individuals at risk for prolonging the endoscopy procedure:&#xD;
             severe chronic pulmonary disease, severe food retention in the stomach on endoscopy 7.&#xD;
             Individuals with a history of other chronic disease potentially causative of&#xD;
             gastrointestinal symptom: 8. Acute or chronic renal insufficiency 9. Known psychiatric&#xD;
             disease 10. Eating disorders 11. Women who are pregnant. A urine pregnancy test is&#xD;
             routinely obtained on all females immediately prior to endoscopic procedures.&#xD;
&#xD;
             12. Individuals with contraindications for endoscopy, including bleeding abnormalities&#xD;
             13. Allergy to eggs preventing sedation with propofol and/or gastric emptying test 14.&#xD;
             Allergy to wheat preventing ingestion of the SmartBar 15. Significant dysphagia 16.&#xD;
             Prior inflammatory bowel disease 17. Prior diverticulitis 18. History of gastric&#xD;
             bezoar 19. History of Crohn's disease 20. Chronic frequent NSAID use 21. Cardiac&#xD;
             medical devices (insulin pumps, continuous glucose monitors are permitted) 22.&#xD;
             Presence or prior use of gastric stimulator 23. History of any gastric/pyloric&#xD;
             injection of botulinum toxin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Serrano, MD. PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Hamilton, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pamkaj Pasricha, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henry Parkman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry P Parkman, MD</last_name>
    <phone>(215) 707-7579</phone>
    <email>henry.parkman@temple.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Silver</last_name>
      <email>paul.silver@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Henry P Parkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center (TTUHSC)</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fisher R, Cohen S. Physiological characteristics of the human pyloric sphincter. Gastroenterology. 1973 Jan;64(1):67-75.</citation>
    <PMID>4683856</PMID>
  </reference>
  <reference>
    <citation>Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592-622. Review.</citation>
    <PMID>15521026</PMID>
  </reference>
  <reference>
    <citation>Desipio J, Friedenberg FK, Korimilli A, Richter JE, Parkman HP, Fisher RS. High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterol Motil. 2007 Mar;19(3):188-95.</citation>
    <PMID>17300288</PMID>
  </reference>
  <reference>
    <citation>Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25.</citation>
    <PMID>3699409</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Public use complete database will be submitted to the NIDDK Data Repository</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>By the end of the funding period</ipd_time_frame>
    <ipd_access_criteria>Application through NIDDK Data Repository; IRB approval</ipd_access_criteria>
    <ipd_url>http://repository.niddk.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

